Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications

J. Crawford¹, C. Caserta² & F. Roila²
On behalf of the ESMO Guidelines Working Group*

¹Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, USA; ²Department of Medical Oncology, S. Maria Hospital, Terni, Italy

**definition of febrile neutropenia**

Febrile neutropenia (FN) is defined as a rise in axillary temperature to >38.5°C for a duration of >1 h while having an absolute neutrophil count (ANC) of <0.5 × 10⁹/l.

**incidence of FN, complication rates and mortality**

Despite relatively high rates of low neutrophil count during standard-dose chemotherapy regimens for malignancies other than acute leukaemias, rates of FN, other complication rates and mortality rates are relatively low for most standard chemotherapies (Table 1).

These rates do not justify the systematic use of haematopoietic growth factors (hGFs) such as granulocyte colony-stimulating factor (G-CSF) or its pegylated form (pegfilgrastim) in prophylaxis of chemotherapy-induced neutropenia unless the risk of FN exceeds 20%, or there are special circumstances as outlined below. Colony-stimulating growth factors should be avoided in patients who are not at high risk for FN or neutropenic complications. The use of hGFs for treatment of FN is also not recommended, except in settings with increased morbidity and mortality, including sepsis, tissue infection and prolonged neutropenia. These agents should be particularly avoided in patients with infections not related to neutropenia, such as community- or hospital-acquired pneumonia [I, A].

**indication for primary prophylaxis of FN by hGFs**

Table 2 describes the indications for primary prophylaxis of FN by hGFs and Table 3 gives examples of chemotherapy regimens with a risk of FN of ~20%.

**special situations for use of hGFs for standard therapy**

Table 4 describes special situations for the use of hGFs for standard therapy.

**dose schedule, route of application of G-CSF and pegfilgrastim**

Use 5 µg/kg/day of G-CSF subcutaneously (s.c.) 24–72 h after the last day of chemotherapy until sufficient/stable post-nadir ANC recovery (achieving a target ANC of >10 × 10⁹/l is not necessary). Pegfilgrastim, injected s.c. as a single dose of either 100 µg/kg (individuated) or of a total dose of 6 mg (general approach), is considered equally effective [I, A].

**note**

Primary prophylaxis with G-CSF is not indicated during chemoradiotherapy to the chest due to the increased rate of bone marrow suppression associated with an increased risk of complications and death [I, A].

There is also a risk of worsening thrombocytopenia when hGFs are given immediately before or simultaneously with chemotherapy.

There is a possible risk of subsequent acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) in women receiving adjuvant chemotherapy for breast cancer and hGFs. However, this is confounded by the higher doses of chemotherapy received by patients receiving hGFs compared with those receiving standard dose reductions. Long-term follow-up of dose-dense adjuvant chemotherapy where total dose is the same has not demonstrated any difference in leukaemic risk. If an increased risk is confirmed in some settings, the absolute risk is low (1.8% compared with 0.7% within 48 months of breast cancer diagnosis) and, therefore, the benefits of hGFs still outweigh the risk.

**use of G-CSF and pegfilgrastim in high-risk situations**

Therapy of acute leukaemias, autologous and allogeneic stem cell transplantations (TPLs) lead to higher risks of FN and potentially lethal complications.
Incidence of FN in high-risk situations: regular during autologous and allogeneic peripheral blood stem-cell (PBSC) TPLs and bone marrow TPL, during graft failure, in 35%–48% of AML cases at diagnosis and in 13%–30% during acute lymphoblastic leukaemia (ALL) induction chemotherapy.

Mortality: 0%–10% in autologous TPL, highly variable in allogeneic TPL, 80% during graft failure, 20%–26% during the first 2 months in AML and 2%–10% during induction of ALL.

indications for granulopoietic CSFs in high-risk situations

Table 5 describes the indications for granulopoietic CSFs in high-risk situations.

G-CSF after autologous stem-cell TPL

- Marrow TPL: start of hGF. Application may safely be postponed until days 5–7 [I]. The recommended dose of G-CSF is 5 μg/kg daily.
- PBSC TPL: short acceleration of recovery of ANC [I] does not consistently translate into relevant clinical
benefit. In standard-risk patients outside trials are not recommended.

**G-CSF after allogeneic TPL**

Reasonable after marrow TPL. Clinical benefit restricted to recovery of ANC. Start 5–7 days after TPL is sufficient [I, A]. Insufficient data for TPL with allo-PBSC.

**mobilization of PBSCs**

**autologous PBSC**

hGFs ± chemotherapy are effective. The recommended dose of G-CSF is 10 µg/kg daily for 7–10 days before apheresis, with or without chemotherapy. hGF-mobilized PBSCs are superior in terms of recovery of ANC to marrow stem cells plus post-infusion hGFs [I, A].

**allogeneic PBSC**

Donor convenience, recovery of ANC hastened, no increased rate of acute graft-versus-host disease. Faster ANC recovery after PBSC compared with marrow stem cells. The recommended dose of G-CSF is 10 µg/kg daily for 7–10 days before apheresis, with or without chemotherapy.

**special comments on CSFs as a treatment for radiation injury**

The use of CSFs as treatment for radiation injury is shown in Table 6.

**note**

Levels of Evidence [I–V] and Grades of Recommendation [A–D] as used by the American Society of Clinical Oncology are given in square brackets. Statements without grading were considered justified standard clinical practice by the expert authors and the ESMO faculty.

**Table 5. Indications for G-CSFs in high-risk situations**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Use of hGFs</th>
<th>Parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autologous marrow transplant</td>
<td>Yes</td>
<td>ANC [I], fever [I, C], infection [I, C], i.v. antibiotics [I, C] Not affected: infectious mortality [I, A], overall survival [I, A]</td>
</tr>
<tr>
<td>Autologous hGF PBSC TPL after reinfusion</td>
<td>Controversial ANC [I]</td>
<td>Not affected: infectious mortality [I, A], overall survival [I, A]</td>
</tr>
<tr>
<td>Allogeneic marrow transplant</td>
<td>Yes</td>
<td>ANC [I, A] Other parameters inconsistent</td>
</tr>
<tr>
<td>Graft failure</td>
<td>Yes</td>
<td>Mortality [III–IV, B]</td>
</tr>
<tr>
<td>AML</td>
<td>No (trials)</td>
<td>ANC [I, A]</td>
</tr>
<tr>
<td>MDS</td>
<td>No</td>
<td>Not affected: infectious mortality [I, C], overall survival [I, C]</td>
</tr>
<tr>
<td>ALL</td>
<td>Controversial</td>
<td>ANC [I, A] Not consistently affected: severe infections, infectious mortality, hospitalization, survival. Increased rates of secondary leukaemia have been reported in childhood ALL treated with G-CSF 6 radiotherapy [III, C]</td>
</tr>
</tbody>
</table>

**Table 6. Lethal doses of total body radiotherapy (accidental or intentional)**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Clinical outcome</th>
<th>Use of CSFs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doses of 3–10 Gy</td>
<td>Probable or certain death from bone marrow failure</td>
<td>Yes</td>
</tr>
<tr>
<td>Doses &lt;3 Gy</td>
<td>Survival with excellent nursing care</td>
<td>No</td>
</tr>
<tr>
<td>Doses &gt;10 Gy</td>
<td>Death due to injury to other organs such as gastrointestinal tract</td>
<td>No</td>
</tr>
</tbody>
</table>

**literature**

7. Kuderer NM, Dale DC, Crawford J et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor in febrile neutropenia and mortality in adult...


